Vital Therapies Cultura de la Empresa

Mr. Robert A. Ashley, M.A. serves as the Chief Operating Officer and President of Virionics Corporation. Mr. Ashley serves as Chief Executive Officer of Ashley BioPharm LLC. He has been the Chief Technical Officer and Executive Vice President at Vital Therapies, Inc. since September 2013. He served as Chief Operating Officer of Vital Therapies, Inc. since May 2008 until September 2013. He is responsible for the management and integration of VTI's regulatory and clinical strategy worldwide. His career in the pharmaceutical industry extends over 26 years. He served as the President, Chief Executive Officer and Chairman of the Board of Amplimed Corp. from 2004 to March 2007. From 1994 to 2003, he served in various capacities with CollaGenex Pharmaceuticals Inc. He served as a Consultant of CollaGenex Pharmaceuticals Inc. until December 2004. He served as Senior Vice President of Commercial Development at CollaGenex Pharmaceuticals from January 1999 to February 27, 2004. He joined Collagenex in September 1994 as Vice President, Commercial Development and Managing Director of CollaGenex International Ltd. From 1989 to September 1994, Mr. Ashley was employed by Bristol-Myers Squibb Company and its predecessor, Squibb Corp., in various positions including product development, commercial and business development and most recently as Director, Business Development where he was responsible for the worldwide product and market development of several new drugs. From 1979 to 1989, Mr. Ashley held various positions at Amersham International (UK) Ltd., including research, development, manufacturing, sales and marketing positions, as well as worldwide product development and product launch positions. He has been a Director of Imcor Pharmaceutical Co. since 2004. He served as Director of AmpliMed Corporation. He is the author of several scientific papers and is the inventor of several issued and pending patents. Mr. Ashley received his MA in Biochemistry from St. Peter's College, Oxford University.

Dr. Duane Nash, M.D., J.D., M.B.A. has been the President of Vital Therapies, Inc. since March 08, 2016. Dr. Nash served as the Chief Business Officer at Vital Therapies, Inc. from March 19, 2012 to March 8, 2016 and also served as its Executive Vice President from May 2013 to March 2016. He served as Medical Director at Vital Therapies, Inc. from March 19, 2012 to May 2013. He served as Senior Vice President in Equity Research at Wedbush PacGrow Life Sciences. He served as Senior Vice President at Wedbush Securities Inc., Research Division. He used to cover cardiac, hepatic and regenerative medicines at the firm. He was an Healthcare Research Analyst at Pacific Growth Equities, LLC, Research Division. He has been an Independent Director of Akebia Therapeutics, Inc. since 2013. He served as a Director of Aerpio Pharmaceuticals, Inc. (formerly Aerpio Therapeutics, Inc.). He has practiced as an Attorney for six years. He was employed at Davis Polk & Wardwell LLP, where he practiced intellectual property litigation, as well as patent evaluation and strategy in the merger and acquisition context. He worked at two other Bay Area law firms and also completed his internship in General Surgery at the University of California at San Francisco, where he served as a member of the liver transplant team. According to STARMINE and Thomson Reuters, Dr. Nash is ranked first among 66 equity research analysts nationwide who publish in the biotechnology market, based on prior 12 month return on recommendations. He is a California-licensed Physician at Medical Board of California and also an inactive member of the California Bar. Dr. Nash holds his J.D. from the University of California at Berkeley, his M.D. from Dartmouth Medical School, an M.B.A. from the University of Oxford and a B.A. in Biology from Williams College.

Mr. Michael V. Swanson, also known as Mike, M.B.A., has been Chief Financial Officer and Treasurer at Vital Therapies, Inc. since August 2013 and September 06, 2013 respectively. Mr. Swanson has been Executive Vice president of Vital Therapies, Inc since March 2016. He served as the Chief Financial Officer at Amira Pharmaceuticals, Inc. since June 2008. Mr. Swanson served as Chief Financial Officer and Vice President of Finance of Prometheus Laboratories Inc. from July 2000 to December 2007. He served as Chief Financial Officer of Panmira Pharmaceuticals, LLC. He served as Senior Vice President of Finance of Prometheus Laboratories Inc. from January 2007 to June 1, 2008 and its Principal Accounting Officer. He also served as Secretary of Prometheus Laboratories Inc., from May 2002 to December 2007 and also as its Chief Accounting Officer. He served as Senior Vice President and Chief Financial Officer of Advanced Tissue Sciences where he served for over 10 years, where he was responsible for all finance and accounting matters, information systems, legal matters and offices services. He has over 30 years of experience in finance and accounting, including 17 years of Chief Financial Officer -level experience in life sciences and specialty pharmaceutical companies. He served as Director of Finance at Fisher Scientific Group Inc., and at its parent, The Henley Group, Inc. Mr. Swanson worked for the public accounting firm of Deloitte Haskins & Sells (now Deloitte & Touche LLP) advancing to the position of Audit Manager before joining The Henley Group. Mr. Swanson Received an MBA from the University of Southern California and a BS in Business Administration from the California Polytechnic State University at San Luis Obispo. He is a Certified Public Accountant.

Mr. Aron P. Stern, M.B.A. has been the Chief Administrative Officer of Vital Therapies, Inc. since August 2013 and served as its Secretary since October 2005 until February 2015. Mr. Stern served as Chief Financial Officer, Treasurer and Vice President of Vital Therapies, Inc. since June 2003 until September 06, 2013. He has over 20 years of experience in capital formation, acquisitions, financial strategy and financial and operational management in growth-stage high technology and biotechnology companies. Mr. Stern has been employed at biomedical companies: from 1989 to 1992 as Director, Finance and Administration at Isis Pharmaceuticals, Inc., and from 1992 to 1998 as Vice President of Finance & Administration and Chief Financial Officer at Protein Polymer Technologies, Inc. He held accounting and financial positions at a variety of high technology companies including Apple Computer, Inc. For 9 years, he served as Chief Financial Officer of Protein Polymer Technologies Inc., 4-D Neuroimaging and for 3 years with VitaGen. He serves as a Director of Vital Therapies (Beijing), Co. Ltd. Mr. Stern received a B.S. degree in Economics and Business Administration and an M.B.A. in Finance and Marketing from the University of California ??? Berkeley.

Andrew Henry serves as the Sr. Vice President of Vital Therapies, Inc.. Andrew started at Vital Therapies, Inc. in Sep of 2018. Andrew currently resides in the Greater San Diego Area.